SynthesisFrontiers in immunology2026
Efficacy and safety of B7-H3-targeted antibody-drug conjugates in previously treated small cell lung cancer: a systematic review and meta-analysis with a contextual comparison to topotecan.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: B7-H3-targeted antibody-drug conjugates (B7-H3-targeted ADCs) have shown promising antitumor effects in patients with previously treated small cell lung cancer (SCLC), yet the available evidence on their efficacy and safety has not been systematically synthesized. This study aimed to systematically evaluate the efficacy and safety of B7-H3-targeted ADCs and contextualize their clinical outcomes against standard-dose intravenous topotecan. Methods: This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. PubMed, Embase, and the Cochrane Library were searched from inception to July 7, 2026. Prospective single-arm studies of B7-H3-targeted ADCs and randomized controlled trials (RCTs) with separately extractable topotecan arms were included. Study quality was assessed using the Newcastle-Ottawa Scale and Cochrane RoB 2 tool. Random-effects models were used to pool efficacy and safety outcomes. Evidence from the two treatment groups was synthesized separately. Results for B7-H3-targeted ADCs were descriptive, whereas topotecan was used solely as an external clinical benchmark; therefore, the contextual comparison should not be interpreted as a direct comparative estimate. Results: Ten studies were included, comprising four prospective single-arm studies of B7-H3-targeted ADCs and six RCTs with eligible topotecan arms. For B7-H3-targeted ADCs, the pooled objective response rate (ORR) and disease control rate (DCR) were 54% (95% CI: 46%-62%) and 89% (95% CI: 85%-92%), respectively. The pooled median duration of response and median progression-free survival were both 5.6 months (95% CI: 4.8-6.4 and 4.7-6.5 months, respectively). The pooled incidences of any-grade and grade ≥3 treatment-related adverse events were 99% (95% CI: 98%-100%) and 61% (95% CI: 55%-67%), respectively. In the exploratory contextual analysis, ifinatamab deruxtecan achieved an ORR of 49% (95% CI: 41%-57%) and a DCR of 87% (95% CI: 81%-92%), whereas the corresponding estimates for topotecan were 18% (95% CI: 15%-22%) and 65% (95% CI: 61%-69%). Overall, the exploratory comparison showed numerically higher efficacy estimates and selected safety differences favoring ifinatamab deruxtecan compared with topotecan. Conclusions: B7-H3-targeted ADCs show promising clinical activity in patients with previously treated SCLC. In the exploratory contextual comparison, ifinatamab deruxtecan showed numerically favorable efficacy estimates and selected safety outcomes compared with topotecan. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD420251237597, version 3.0.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.